Member Info for RichTheNewbie

A great end to the week and all everyone's talking about is Barwick's incoherent guff!
Suggest everyone (myself included) just logs off and enjoys the weekend instead ;)

could say i could = could say I bought

It doesn't matter what you said.
I could say I could ten trillion shares this week.
Wouldn't make it true.
I do enjoy you saying I talk ****e though. That's like when Donald Trump calls people stupid.

Judging by most of his recent posts being elsewhere it smacks of "sold at the bottom to chase a rainbow somewhere else" ;)

that=than

Are you referring to something other that Knabu?

doggo - I disagree with everything you say as usual. Night night ;)

prise=price

If people sell into the rise then great. That's even better. The company are reducing the shares in issue at a lower price. The value of EVERY INVESTMENT per share has just gone up considerably more.
If the prise rises so much it's not worth continuing the buy back. Great, you can sell if you want, or don't.
The BoD are paid a salary for managing this. They get a reward whether it rises or not. It's quite a handsome reward considering the performance of the company and far in excess of normal fund management charges. They also get the reward from being invested already in most of the companies FFWD has ploughed money into. Some would say that's a conflict of interest it's such a benefit to them. Yeah giving themselves a big dividend on top would just about top it off and rubber stamp that this is being run for the benefit of the BoD and not investors.

Matador - Probably true. However mostly confidence stems from the SP as always.
Hence, for all the reasons I've mentioned, doing the dividend just makes things worse, and doing things like investing in something that looks good (a bit more EMMAC perhaps like you mention), or a buyback, or a combination of both would be fine.
I think the key for new investments would be balancing the chance of good reward without being a play that's going to take years to see rewards from. EMMAC is looking good, but for that reason, I'm not sure we'd get a great price for more investment now.
I reckon there are probably better opportunities for a higher reward out there, for companies like FFWD that could (assuming a LEAP sale) provide someone a million or two in cash to get them to the next level quickly.

And yes - Factom finally sorting funding - and us getting back our cash plus 25% would be nice too ;)

Even worse than that, it would signal to the market that the BoD have no confidence in their ability to generate more money, using the resulting increased cash in the business.

It doesn't matter what it sells for. The dividend is a bad idea no matter how many times you bang on about it. For the reasons cited.

And further benefiting if there's any success from any other investment as the lower number of shares increases your return from ANY of the other investments.

It's not a payout if the stock price takes a tumble. Which it would, because LEAP will account for a significant chunk of the current market cap, so you get cash in one hand whilst it disappears from another.
I think you'd see far more value returned to shareholders by retaining the cash and using it to buy back shares whilst the company is considerably undervalued.
If you want to take the cash then, you can, by selling shares at a higher price, or if you want to hold you can, benefiting from the more valuable company continuing to rise as the free float is reduced.

That would be a terrible idea. Everyone would just sell up and leave. Myself included. Definitely wouldn't invest any more money in.
The only multiples of the current share price would be multiples lower as a large chunk of the value is removed from the company.

Well I don't have a plan as such. ;)
I'll just likely reinvest profit if one of my stocks goes nuts (in a good way).

I think this is how the Market Makers take advantage during low volume lulls.
They stock up (not huge amounts but a good chunk each) mopping up all the bored PI sells.
Then when some good news comes they've got a nice buffer of cheap shares.
PI's are regularly their own worst enemy and all claim to buy low and sell high but in reality you can see from the trade feeds that's not the case and usually the opposite.
If I'm really lucky I'll get some good news on my biotech one in this quarter or the next (impossible to predict) and then I can plough significant proceeds into here if it's still low :)

Back to SNG related matters.

Two PXS news releases today, a big presentation focusing heavily on LOXL2 from the Aus Biotech conference, and a related ASX update.

The most relevant bits from the update are:
"Pharmaxis has recently presented data at scientific conferences and in scientific publications detailing its unique proprietary assays that, for the first time, allow all of the LOX enzyme family to be measured in serum and tissue, even at very low levels. These data demonstrate that LOXL2 in particular has a relatively fast turnover in human serum and suggests that an effective drug will need to both penetrate fibrotic tissue and be present in concentrations high enough to inhibit LOXL2 at all times. Pharmaxis has used this unique assay technology in the development and assessment of all its current LOX and LOXL2 inhibitors."

"Whilst there are several excellent publications demonstrating the increase in LOXL2 enzyme levels in patients with fibrotic diseases of the lung, liver, kidney, heart, and some cancers, the importance of LOXL2 has been put in doubt by the failure of the one competitive LOXL2 inhibitor drug to have been trialled in patients; Gilead’s LOXL2 antibody simtuzumab. Gilead
commented in the publication of its failed IPF study that their lack of an assay for LOXL2 inhibition limited their ability to confirm adequate target inhibition.
The risk sensitivities of potential commercial partners for our LOXL2 inhibitor program were understandably heightened by the historic simtuzumab clinical failures but importantly, the work Pharmaxis has undertaken in assay sensitivity has provided very reassuring data. Over the course of this year, we have been able to reanalyse samples from existing studies and conduct new preclinical studies that have clearly shown the link between LOXL2 inhibition in diseased organs, a
reduction in collagen crosslinking which is a hallmark of fibrosis and clinical effect as measured by the area of fibrosis. This data has energised the partnering process by underlining the relevance of LOXL2 and the superiority of our compounds. We are currently pursuing a number of different partnering options to enable this drug to commence phase 2 efficacy studies in patients with IPF or NASH.”

Partnering process still listed as to conclude H2 - 2019 in the presentation. So all looking good. Looks like the market was basically spooked by the Gilead failure but they have the data to show their drug is top notch and is much less likely to suffer the same failure due to testing they've done.

I understood what you were getting at doggo re:the 30ish min mark.
Just had to vent frustration at the bits when she spoke....or should I say went "uhhhhhhh".

I can see what you're referring to doggo - however that interview is very very annoying......just because the interviewer is clearly a total airhead who doesn't understand anything......I can imagine why she has a certain amount of "viewers" though......